JP6054876B2 - アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン - Google Patents

アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン Download PDF

Info

Publication number
JP6054876B2
JP6054876B2 JP2013544747A JP2013544747A JP6054876B2 JP 6054876 B2 JP6054876 B2 JP 6054876B2 JP 2013544747 A JP2013544747 A JP 2013544747A JP 2013544747 A JP2013544747 A JP 2013544747A JP 6054876 B2 JP6054876 B2 JP 6054876B2
Authority
JP
Japan
Prior art keywords
vector
adenoviral vector
vectors
rad35
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013544747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503206A5 (enExample
JP2014503206A (ja
Inventor
ジェー サリバン ナンシー
ジェー サリバン ナンシー
ジェー ネーブル ゲイリー
ジェー ネーブル ゲイリー
アシドゥ クレモン
アシドゥ クレモン
チェン チェン
チェン チェン
グラッツィア パウ マリア
グラッツィア パウ マリア
ハウトスミット ヤープ
ハウトスミット ヤープ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goverment Of United States, Represented By Secretary Of Department Of Health And Human Services AS
US Department of Health and Human Services
Original Assignee
Goverment Of United States, Represented By Secretary Of Department Of Health And Human Services AS
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goverment Of United States, Represented By Secretary Of Department Of Health And Human Services AS, US Department of Health and Human Services filed Critical Goverment Of United States, Represented By Secretary Of Department Of Health And Human Services AS
Publication of JP2014503206A publication Critical patent/JP2014503206A/ja
Publication of JP2014503206A5 publication Critical patent/JP2014503206A5/ja
Application granted granted Critical
Publication of JP6054876B2 publication Critical patent/JP6054876B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013544747A 2010-12-14 2011-12-14 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン Active JP6054876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42295410P 2010-12-14 2010-12-14
US61/422,954 2010-12-14
PCT/US2011/064944 WO2012082918A1 (en) 2010-12-14 2011-12-14 Adenovirus serotype 26 and serotype 35 filovirus vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016206679A Division JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Publications (3)

Publication Number Publication Date
JP2014503206A JP2014503206A (ja) 2014-02-13
JP2014503206A5 JP2014503206A5 (enExample) 2015-01-29
JP6054876B2 true JP6054876B2 (ja) 2016-12-27

Family

ID=46245095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013544747A Active JP6054876B2 (ja) 2010-12-14 2011-12-14 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン
JP2016206679A Active JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016206679A Active JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Country Status (14)

Country Link
US (1) US9701718B2 (enExample)
EP (1) EP2655604B1 (enExample)
JP (2) JP6054876B2 (enExample)
KR (1) KR101879892B1 (enExample)
CN (1) CN103370411B (enExample)
AU (1) AU2011343798B2 (enExample)
BR (1) BR112013014712B1 (enExample)
CA (1) CA2821289C (enExample)
DK (1) DK2655604T3 (enExample)
EA (1) EA029504B1 (enExample)
ES (1) ES2676196T3 (enExample)
PL (1) PL2655604T3 (enExample)
WO (1) WO2012082918A1 (enExample)
ZA (1) ZA201304260B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701718B2 (en) 2010-12-14 2017-07-11 Janssen Vaccines & Prevention B.V. Adenovirus serotype 26 and serotype 35 filovirus vaccines
SG11201610446XA (en) 2014-06-26 2017-01-27 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US10561721B2 (en) 2014-09-03 2020-02-18 Bavarian Nordic A/S Methods and compositions for inducing protective immunity against filovirus infection
MX2017002890A (es) 2014-09-03 2017-11-13 Bavarian Nordic As Métodos y composiciones para potenciar respuestas inmunitarias.
CN112121160A (zh) 2014-09-26 2020-12-25 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
US20180052173A1 (en) 2015-03-18 2018-02-22 Janssen Vaccines & Prevention B.V. Assays for recombinant expression systems
TWI707039B (zh) 2015-12-15 2020-10-11 荷蘭商傑森疫苗防護公司 人類免疫缺陷病毒抗原、載體、組成物、及其使用方法
MX2018009997A (es) 2016-02-18 2019-02-07 Int Flavors & Fragrances Inc Composiciones de cápsulas de poliurea.
MX2018011341A (es) 2016-03-18 2019-07-04 Int Flavors & Fragrances Inc Microcápsulas de sílice y métodos para prepararlas.
AU2017286375B2 (en) 2016-06-16 2019-04-18 Janssen Vaccines & Prevention B.V. HIV vaccine formulation
EP4438132A3 (en) 2016-07-01 2025-01-15 International Flavors & Fragrances Inc. Stable microcapsule compositions
WO2018011198A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018011768A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
MX2019003078A (es) 2016-09-16 2019-07-08 Int Flavors & Fragrances Inc Composiciones de microcapsulas estabilizadas con agentes de control de la viscosidad.
US20180085291A1 (en) 2016-09-28 2018-03-29 International Flavors & Fragrances Inc. Microcapsule compositions containing amino silicone
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
US20180346648A1 (en) 2017-05-30 2018-12-06 International Flavors & Fragrances Inc. Branched polyethyleneimine microcapsules
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
CN111163799A (zh) 2017-07-28 2020-05-15 扬森疫苗与预防公司 用于异源repRNA免疫接种的方法和组合物
WO2019099970A1 (en) 2017-11-20 2019-05-23 Janssen Pharmaceuticals Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
MX2020006471A (es) 2017-12-19 2020-09-22 Janssen Sciences Ireland Unlimited Co Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
EP4667651A2 (en) 2018-04-27 2025-12-24 International Flavors and Fragrances Inc. Stable polyurea microcapsule compositions
WO2020016394A1 (en) 2018-07-20 2020-01-23 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
CN112770770A (zh) 2018-09-25 2021-05-07 扬森疫苗与预防公司 共定位施用疫苗组分诱导针对人类免疫缺陷病毒的免疫应答的方法
CN120694898A (zh) 2018-12-18 2025-09-26 国际香料和香精公司 瓜尔胶微胶囊
MX2021013950A (es) 2019-05-14 2022-01-04 Janssen Biotech Inc Eliminacion eficaz de impurezas usando un proceso de diafiltracion.
US20230075527A1 (en) 2020-01-31 2023-03-09 Janssen Pharmaceuticals, Inc Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
IL298055A (en) 2020-05-11 2023-01-01 Janssen Pharmaceuticals Inc Stabilized coronavirus spike protein fusion proteins
BR112022026408A2 (pt) 2020-06-29 2023-01-17 Janssen Vaccines & Prevention Bv Combinação vacinal contra infecção pelo vírus sincicial respiratório
JP2023532369A (ja) 2020-07-06 2023-07-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド 安定化されたコロナウイルススパイクタンパク質融合タンパク質
EP4178613A1 (en) 2020-07-08 2023-05-17 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
MX2022002609A (es) * 2020-08-22 2022-06-08 Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte Vector de expresion para el desarrollo de un agente inmunobiologico para inducir inmunidad especifica contra el virus de sindrome respiratorio agudo grave sars-cov-2 (variantes).
MX2023009738A (es) 2021-02-19 2023-08-30 Janssen Vaccines & Prevention Bv Antigenos de rsv fb prefusion estabilizados.
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
CN118234739A (zh) 2021-04-01 2024-06-21 扬森疫苗与预防公司 稳定的融合前piv3 f蛋白
EP4124383A1 (en) 2021-07-27 2023-02-01 International Flavors & Fragrances Inc. Biodegradable microcapsules
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023026182A1 (en) 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4154974A1 (en) 2021-09-23 2023-03-29 International Flavors & Fragrances Inc. Biodegradable microcapsules
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
EP4590690A1 (en) 2022-09-23 2025-07-30 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
EP4590689A1 (en) 2022-09-23 2025-07-30 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
EP4598939A1 (en) 2022-10-06 2025-08-13 MSD International Business GmbH Stabilized pre-fusion piv3 f proteins
EP4406641A1 (en) 2023-01-26 2024-07-31 International Flavors & Fragrances Inc. Biodegradable microcapsules containing low log p fragrance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852324B1 (en) * 1997-12-23 2005-02-08 The United States Of America As Represented By The Department Of Health And Human Services Immunization for ebola virus infection
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
CA2776522C (en) * 2001-10-01 2015-02-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
JP4495588B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 安定なアデノウイルスベクターおよびその増殖方法
PT1497438E (pt) 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
WO2004037294A2 (en) * 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
WO2005012538A2 (en) * 2003-08-01 2005-02-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Accelerated vaccination
US8101739B2 (en) 2004-09-27 2012-01-24 The United States Of America As Represented By The Department Of Health And Human Services Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector
ES2358523T3 (es) * 2004-10-13 2011-05-11 Crucell Holland B.V. Vectores adenovirales mejorados y usos de los mismos.
NZ553889A (en) 2004-10-13 2009-11-27 Crucell Holland Bv Replication-defective adenovirus comprising a chimeric hexon protein and replaced hypervariable ragions HVR1-7
EA016648B1 (ru) * 2004-10-14 2012-06-29 Круселл Холланд Б.В. Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии
WO2007104792A2 (en) * 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
EP1998804B1 (en) * 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US20110091496A1 (en) * 2008-01-19 2011-04-21 Graham Barney S Methods and compositions for the delivery of vaccines to disrupted epithelium
US9701718B2 (en) 2010-12-14 2017-07-11 Janssen Vaccines & Prevention B.V. Adenovirus serotype 26 and serotype 35 filovirus vaccines

Also Published As

Publication number Publication date
US9701718B2 (en) 2017-07-11
AU2011343798A1 (en) 2013-07-11
KR20140019304A (ko) 2014-02-14
US20140017278A1 (en) 2014-01-16
CN103370411A (zh) 2013-10-23
CN103370411B (zh) 2016-05-04
KR101879892B1 (ko) 2018-08-17
EP2655604A4 (en) 2015-01-28
CA2821289A1 (en) 2012-06-21
BR112013014712A2 (pt) 2017-06-06
EP2655604A1 (en) 2013-10-30
JP6268258B2 (ja) 2018-01-24
AU2011343798B2 (en) 2016-07-14
EA201390866A1 (ru) 2014-05-30
ZA201304260B (en) 2021-05-26
ES2676196T3 (es) 2018-07-17
JP2017048207A (ja) 2017-03-09
BR112013014712B1 (pt) 2021-03-02
PL2655604T3 (pl) 2019-02-28
WO2012082918A1 (en) 2012-06-21
DK2655604T3 (en) 2018-08-06
EA029504B1 (ru) 2018-04-30
JP2014503206A (ja) 2014-02-13
CA2821289C (en) 2019-05-21
EP2655604B1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
JP6054876B2 (ja) アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン
US11913013B2 (en) Chimpanzee adenoviral vector-based filovirus vaccines
Geisbert et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge
AU2015311868B2 (en) Methods and compositions for enhancing immune responses
CN107454848B (zh) 用于诱导针对丝状病毒感染的保护性免疫的方法和组合物
JP5046941B2 (ja) エボラ及び他のウイルスに対する防御に最適化されたワクチン
WO2016187613A1 (en) Methods and compositions for inducing protective immunity against filovirus infection and/or disease
US10925955B2 (en) Methods and compositions for inducing protective immunity against a Marburg virus infection
OA19216A (en) Methods and compositions for inducing protective immunity against a Marburg virus infection.
HK1239544A1 (en) Methods and compositions for inducing protective immunity against filovirus infection
HK1239544B (en) Methods and compositions for inducing protective immunity against filovirus infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161021

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161201

R150 Certificate of patent or registration of utility model

Ref document number: 6054876

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250